Dermira, Inc.
275 Middlefield Road
Suite 150
Menlo Park
California
94025
United States
Tel: (650) 421-7200
Fax: 650-365-3410
Website: http://www.dermira.com/
Email: info@dermira.com
112 articles about Dermira, Inc.
-
Dermira to Report Second Quarter 2019 Results and Host Conference Call on Wednesday, August 7, 2019
7/31/2019
Dermira, Inc., a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, will report financial results for the quarter ended June 30, 2019 and provide an operational update after market close on Wednesday, August 7, 2019.
-
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...
-
Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis
6/25/2019
Lebrikizumab is a novel, investigational anti-IL-13 monoclonal antibody under development for the treatment of people with moderate-to-severe atopic dermatitis
-
The deal comes as Dermira plans to initiate Phase III studies in the U.S.
-
Dermira to Present at the Raymond James Life Sciences and MedTech Conference
6/11/2019
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present at the Raymond James Life Sciences and MedTech Conference in New York on June 18, 2019 at 2:25 p.m. ET.
-
Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update
5/7/2019
Dermira, Inc. reported financial results for the quarter ended March 31, 2019, provided a corporate update and issued 2019 financial guidance.
-
Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019
4/30/2019
Dermira, Inc. will report financial results for the quarter ended March 31, 2019 and provide an operational update after market close on Tuesday, May 7, 2019.
-
Dermira to Present at the 18th Annual Needham Healthcare Conference
4/3/2019
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in a fireside chat at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 12:50 p.m. ET.
-
When it comes to biotech and pharma innovation few places stand out like the Biotech Bay. The area is home to a plethora of innovative companies that are shaping the future of medical treatment for a variety of diseases and conditions on a daily basis.
-
The stock is up more than 100 percent after the company announced positive results from a Phase IIb study of lebrikizumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis.
-
Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis
3/18/2019
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced positive results from a Phase 2b dose-ranging study of lebrikizumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis.
-
Movers and Shakers for Sept. 10
9/10/2018
Let's take a look at who made a splash in the pharma and biotech world the past week. -
The U.S. Food and Drug Administration (FDA) was busy during the first half of this year with more than 20 novel drug approvals. Of those approvals, one-third came in June.
-
Shares of Menlo Park, Calif.-based Dermira jumped more than 10 percent this morning after the U.S. Food and Drug Administration (FDA) approved its therapy for people who have excessive underarm sweating.
-
Dermira plans to shutter the program and move on to more promising compounds.
-
Dermira Showcases Commitment to Hyperhidrosis Education and Treatment at Leading Dermatology Conference
2/12/2018
The event is taking place in San Diego, February 16-20.
-
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/9/2018
The company granted RSUs representing an aggregate of 19,600 shares of Dermira common stock and stock options to purchase an aggregate of 254,075 shares of Dermira common stock.
-
Dermira Initiates Phase IIb Dose-Ranging Study Evaluating Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
1/31/2018
The Phase 2b study is designed to evaluate the safety and efficacy of lebrikizumab as a monotherapy.
-
Dermira Reports Third Quarter 2017 Financial Results and Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients With Primary Axillary Hyperhidrosis
11/7/2017
The FDA's decision on New Drug Application expected by June 30, 2018.
-
Dermira and UCB Agree to End Collaboration Agreement for CIMZIA
11/7/2017
Dermira to transition development and commercialization responsibility for CIMZIA (certolizumab pegol) in psoriasis back to UCB.